the government evaluates the application of the Sinopharm vaccine to boys from 3 years old

The Minister of Health of the Nation, Carla Vizzotti, has a virtual meeting with researchers and referents in the field of medical regulation of the United Arab Emirates (UAE), with the aim of evaluating the possibility of applying the Sinopharm vaccine minors from 3 years old.

The meeting with specialists from the Middle Eastern country is linked because there have already been clinical trials with the vaccine of Chinese origin for less than 3 to 17 years of two doses, with an interval of at least 21 days. As stated, the results they were positive and similar to adults, both in terms of safety and immunogenicity.

“Although children and adolescents usually have covid-19 disease in a mild form, it is essential to progress in their individual protection which will result in a indirect benefit in older populations who present a higher risk of complications and death ”, explained the Minister.

He also stressed the importance of continuing to assess strategies having a positive impact on schooling, as well as the possibilities of collaboration with the United Arab Emirates. produce evidence.

Given “the importance of these studies for our country and the world”, as Vizzotti expressed by videoconference, the Minister researchers invited to present the study and the results, which motivated the approval, before representatives of the National Administration of Drugs, Food and Medical Technologies (ANMAT) and the National Vaccination Commission (CoNaIn).

Sinopharm is the vaccine that the Argentine government has bought the most. Currently, contracts reach 30 million doses. This month alone, 8 million are expected. In China, it is already authorized to address minors from 3 years old.

The meeting took place in the presence of the research director and head of the G42 Healthcare Vaccine project, Walid Zaher; the head of international strategic partnerships of G42 Healthcare, Obaid Al Zaabi; and the head of regulatory affairs of the G42 Life Science Cluster, Maimoona Firdous.

The Under-Secretary for Health Strategies, Juan Manuel Castelli, and Argentina’s Ambassador to the United Arab Emirates, Jorge Agustín Molina Arambarri, were also present at the meeting.

In China it is already authorized

One of the big concerns the world is considering today is the vaccination against the coronavirus of the under-18s. The problem is that there are still not too many alternatives to do this.

In June, China approved the use of the Sinopharm vaccine for children aged 3 to 17, an issue that became relevant in our country after it was announced. the purchase of 30 million doses from this laboratory.

But just because the Sinopharm vaccine is approved in China for this age group – like Sinovac, not available in the country – doesn’t mean it be activated for the same in Argentina.

The clinical trial that led to the authorization in the Asian country must be analyzed by the Angat, and ultimately recommend its emergency use to the government.

Now this study has also been added to that of the United Arab Emirates, where they ensure that the results were positive and similar to adults.

LM